AbbVie Inc. (ABBV) stock
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3090% above fair value
$294.55−0.48 (-0.16%)
Close on Nov 16, 2026Market cap $520.50BP/E 83.2Yield 2.26%
AbbVie enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
AbbVie's enterprise value was $587.37B on Nov 11, 2026, against $466.77B a year earlier. Over the last 5 years it ranged from $294.85B to $587.37B, with a median of $369.47B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $587.37B | +25.5% |
| 2025 | Dec 31, 2025 | $468.17B | +23.6% |
| 2024 | Dec 31, 2024 | $378.90B | +17.5% |
| 2023 | Dec 29, 2023 | $322.52B | -6.5% |
| 2022 | Dec 30, 2022 | $345.02B | +11.6% |
| 2021 | Dec 31, 2021 | $309.14B | +23.5% |
| 2020 | Dec 31, 2020 | $250.35B | +57.0% |
| 2019 | Dec 31, 2019 | $159.48B | -9.7% |
| 2018 | Dec 31, 2018 | $176.67B | -3.8% |
| 2017 | Dec 29, 2017 | $183.73B | +39.5% |
| 2016 | Dec 30, 2016 | $131.74B | +10.3% |
| 2015 | Dec 31, 2015 | $119.41B | +6.3% |
| 2014 | Dec 31, 2014 | $112.37B | +25.3% |
| 2013 | Dec 31, 2013 | $89.66B | – |
See a number that looks wrong?